integrated hiv prevention and hcv care for pwid

Conditions: HIV Prevention; HCV; Opioid Use; Intravenous Drug Usage

Summary: the objective of this study is to compare and evaluate two strategies of delivering prep and hepatitis c virus (hcv) treatment to people who inject drugs to determine the best method of providing care. participants will be randomized to one of two treatment arms: on-site integrated care or off-site referral to specialized care.

the first strategy, the on-site integrated care model, provides opioid agonist therapy (oat) clinics and harm reduction sites/syringe access programs (sap) with the tools to offer hiv prevention and hcv treatment on-site. the second strategy, the off-site referrals to specialized care model, connects people who are at risk for contracting hiv with patient navigators who help them access available hiv prevention care and, if necessary, hcv treatment.

Eligibility criteria:
inclusion criteria: individuals must meet the following criteria to be eligible to participate in the rct: 1. be 18-64 years of age 2. report injection drug use in the past 6-months 3. be hiv negative 4. provide informed consent 5. complete a medical release form 6. report living in the vicinity and being able to return for follow-up over 18-months 7. be willing to use a medically acceptable form of contraception throughout the study duration (for women of childbearing potential) 8. be able to communicate in english or french (site dependent) 9. be receiving services at an opioid agonist therapy clinic or a syringe access program individuals must meet the following criteria to be eligible to participate in the qualitative interview: 1. have completed the first 6 months of rct follow up (rct participant interviews); 2. provide informed consent; 3. have contributed to assessments/interviews, intervention and/or treatment follow-ups (staff interviews). exclusion criteria: individuals will be excluded from the rct if they: 1. have any disabling medical conditions as assessed by medical history, physical exam, vital signs, and/or laboratory assessments that in the opinion of the study physician preclude safe participation in the study or ability to provide fully informed consent. 2. have any disabling mental conditions as assessed by medical history and clinical assessment that in the opinion of the study physician precludes safe participation in the study or ability to provide fully informed consent. 3. have chronic renal failure 4. have or have history of decompensated cirrhosis 5. are hiv-positive or have symptoms of an acute hiv infection 6. are pregnant (verified via pregnancy test), are planning to be pregnant during the course of the study, or breastfeeding 7. have an allergy or contraindication to one of the study medications 8. have prior hcv treatment failure with direct-acting antiviral (daa) regimens (except those who were treated, cured the virus, but were re-infected with a new virus) 9. are currently on prep and/or hcv treatment. 10. are currently in prison, in any inpatient overnight facility as required by court of law or have a pending legal action, which may prevent an individual from completing the study.

Keywords: prep hcv treatment injection drug use